Investors Research Corp Increases Holdings in Abbott Laboratories $ABT

Investors Research Corp boosted its stake in Abbott Laboratories (NYSE:ABT) by 7,781.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,305 shares of the healthcare product maker’s stock after purchasing an additional 6,225 shares during the period. Investors Research Corp’s holdings in Abbott Laboratories were worth $572,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ABT. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Price Performance

NYSE ABT opened at $108.29 on Friday. The company has a 50-day moving average price of $104.43 and a two-hundred day moving average price of $100.12. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market cap of $187.38 billion, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.